GNPX Genprex Inc.

6.03
+0.7  (+13%)
Previous Close 5.33
Open 5.05
Price To Book 46.38
Market Cap 167,934,541
Shares 27,849,841
Volume 19,869,685
Short Ratio
Av. Daily Volume 7,914,776
Stock charts supplied by TradingView

NewsSee all news

  1. Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants

    Genprex, Inc. ("Genprex" or the "Company") (Nasd

  2. Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants

    Genprex, Inc. ("Genprex" or the "Company") (Nasd

  3. Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

    Company licenses patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh Results from in vivo animal studies indicate that

  4. Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement

    Genprex, Inc. ("Genprex" or the "Company") (Nasd

  5. Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

    Genprex, Inc. ("Genprex" or the "Company") (Nasd

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 enrolment will not be re-opened - noted February 5, 2020.
Oncoprex With Tarceva
Non-small cell lung cancer (NSCLC)
Phase 1/2 trial to be initiated mid-2020.
Oncoprex in combination with osimertinib
Non-small cell lung cancer (NSCLC)

Latest News

  1. Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants

    Genprex, Inc. ("Genprex" or the "Company") (Nasd

  2. Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants

    Genprex, Inc. ("Genprex" or the "Company") (Nasd

  3. Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

    Company licenses patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh Results from in vivo animal studies indicate that

  4. Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement

    Genprex, Inc. ("Genprex" or the "Company") (Nasd

  5. Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

    Genprex, Inc. ("Genprex" or the "Company") (Nasd

  6. Genprex to Present at NobleCon16 Investor Conference

    Genprex, Inc. ("Genprex" or the "Company") (NASD

  7. Independent Researchers Find Genprex's TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy

    Study results show TUSC2 overexpression decreased thyroid cancer tumor metastasis and increased sensitivity to apoptosis by increasing SMAC/DIABLO and Cytochrome C protein levels

  8. Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering

    Capital raise follows recent Fast Track Designation by the FDA for Company's Oncoprex™ imunogene therapy for NSCLC in combination therapy with AstraZeneca's Tagrisso®

  9. Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market

    Genprex, Inc. ("Genprex" or the "Company") (NASD

  10. Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer

    Lung cancer is the world's leading cause of cancer deaths

  11. Genprex to Present at Biotech Showcase™ 2020 in San Francisco

    Genprex, Inc. ("Genprex" or the "Company") (NASD

  12. Genprex Announces $1.26 Million Registered Direct Offering

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:

  13. Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers

    Company's TUSC2 gene therapy found to increase effectiveness of anti-PD1 immunotherapy and anti-PD1 immunotherapy combined with platinum chemotherapy in humanized mouse model

  14. Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

    Genprex, Inc. (NASDAQ:

  15. MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16th, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap

  16. Genprex to Present at the MicroCap Rodeo Investor Conference

    Genprex, Inc. (NASDAQ:

  17. Genprex's Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support

    Genprex, Inc. (NASDAQ:

  18. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NetworkNewsWire Editorial Coverage: Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX Profile)

  19. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Advances in biotechnology look to deliver promising new treatment options against breast cancer.  Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX

  20. Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019

    Genprex, Inc. (NASDAQ:

  21. Independent Researchers Find Genprex's TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

    A direct target of miR-138, TUSC2 mimics miR-138 knockdown

  22. Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatments

    NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled "Gene Therapy Treatments Offer Hope for Cancer

  23. Genprex (GNPX) Featured in NetworkNewsWire Publication Summarizing Gene Therapy Treatment for Lung Cancer

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and

  24. Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Genprex, Inc. (NASDAQ:

  25. Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

    Genprex, Inc. (NASDAQ:

  26. Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector

    NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of an audio press release broadcast titled, "Record Revenues, Milestone Achievements Indicate

  27. Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Company's Milestone Achievements

    NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and